Allworth Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-484
| Closed | -$1.77K | – | 4219 |
|
|
2024
Q4 | $1.77K | Sell |
484
-331
| -41% | -$1.44K | ﹤0.01% | 3197 |
|
|
2024
Q3 | $4.23K | Hold |
815
| – | – | ﹤0.01% | 2641 |
|
|
2024
Q2 | $2.96K | Sell |
815
-5
| -0.6% | -$17 | ﹤0.01% | 2750 |
|
|
2024
Q1 | $4.04K | Buy |
820
+753
| +1,124% | +$4.46K | ﹤0.01% | 2497 |
|
|
2023
Q4 | $590 | Sell |
67
-65
| -49% | -$533 | ﹤0.01% | 3097 |
|
|
2023
Q3 | $1.51K | Hold |
132
| – | – | ﹤0.01% | 2673 |
|
|
2023
Q2 | $3.34K | Sell |
132
-300
| -69% | -$9.35K | ﹤0.01% | 2278 |
|
|
2023
Q1 | $13.9K | Hold |
432
| – | – | ﹤0.01% | 1656 |
|
|
2022
Q4 | $7.97K | Hold |
432
| – | – | ﹤0.01% | 1754 |
|
|
2022
Q3 | $12K | Buy |
432
+81
| +23% | +$1.64K | ﹤0.01% | 1588 |
|
|
2022
Q2 | $5K | Sell |
351
-17
| -5% | -$262 | ﹤0.01% | 1777 |
|
|
2022
Q1 | $7K | Sell |
368
-959
| -72% | -$14.5K | ﹤0.01% | 1575 |
|
|
2021
Q4 | $22K | Buy |
1,327
+976
| +278% | +$16.3K | ﹤0.01% | 1096 |
|
|
2021
Q3 | $10K | Buy |
351
+51
| +17% | +$1.46K | ﹤0.01% | 1357 |
|
|
2021
Q2 | $9K | Hold |
300
| – | – | ﹤0.01% | 1081 |
|
|
2021
Q1 | $8K | Hold |
300
| – | – | ﹤0.01% | 1045 |
|
|
2020
Q4 | $9K | Buy |
+300
| New | +$7.77K | ﹤0.01% | 867 |
|
Other funds holding RVNC
Allworth Financial's RVNC Position: Q1 2025 in Review
Allworth Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 484 shares — an estimated $1.77K sold.
Allworth Financial first reported a position in RVNC in Q4 2020 and held it in 17 quarters. The position peaked at $22K in Q4 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Allworth Financial reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Allworth Financial sold 484 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.77K.
- Allworth Financial first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 17 quarters.
- Allworth Financial's Revance Therapeutics, Inc. position peaked at $22K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Allworth Financial's 13F filing for Q1 2025, filed 30 Apr 2025.